Valuation : Spruce Biosciences, Inc.

Market Cap 170M 146M 137M 125M 234M 16.1B 235M 1.63B 630M 8.23B 638M 624M 26.19B P/E 2026 *
-2.19x
P/E 2027 * 18.5x
Enterprise Value 106M 91.16M 85.76M 78.27M 146M 10.05B 147M 1.02B 393M 5.14B 398M 389M 16.35B EV / Sales 2026 *
-
EV / Sales 2027 * 0.45x
Free-Float
90.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2022-01-02
Director of Finance/CFO 43 2020-04-30
Chief Tech/Sci/R&D Officer 59 2026-07-26
Director TitleAgeSince
Chairman 73 2017-03-31
Director/Board Member 54 2017-09-30
Director/Board Member 67 2020-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/26 Free

Chief Technology Officer

13,000 0.4723%
6/30/26 Free

Chief Executive Officer

266 0.0249%
5/21/26 Free

Director

1,700 0.1588%
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%+6.28% - - 170M
-0.82%-3.77%-2.49%+14.92% 48.01B
-1.29%-1.22%+404.92%+545.45% 44.44B
-3.20%+0.33%+38.11%+21.39% 42.67B
-1.89%-2.00%+1.45%+82.46% 39.96B
-1.72%-2.61%+13.09%+42.33% 32.75B
-0.17%+3.78% - - 17.74B
-0.07%+1.32%+20.08%+117.95% 16.49B
-0.56%-0.50%+11.39%+31.41% 14.38B
-2.68%-0.56%+73.31%+40.56% 13.4B
Average -1.04%+0.19%+69.98%+112.06% 27B
Weighted average by Cap. -1.53%-1.05%+85.14%+132.84%

Financials

2026 *2027 *
Net sales - 88.56M 76.15M 71.64M 65.38M 122M 8.4B 123M 849M 328M 4.29B 333M 325M 13.66B
Net income -59.59M -51.24M -48.2M -43.99M -82.09M -5.65B -82.52M -571M -221M -2.89B -224M -219M -9.19B 7.76M 6.67M 6.28M 5.73M 10.69M 736M 10.74M 74.37M 28.77M 376M 29.14M 28.5M 1.2B
Net Debt -63.8M -54.86M -51.61M -47.1M -87.89M -6.05B -88.34M -611M -237M -3.09B -240M -234M -9.84B -130M -112M -105M -96.18M -179M -12.35B -180M -1.25B -483M -6.31B -489M -479M -20.09B
Logo Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. It has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.
Employees
22
Date Price Change
26-09-08 US$59.09 +2.00%
26-09-04 US$57.93 +0.38%
26-09-03 US$57.71 -3.28%
26-09-02 US$59.67 +7.32%
26-09-01 US$55.60 -5.71%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
59.09USD
Average target price
147.88USD
Spread / Average Target
+150.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!